



Consolidated Financial Results for the Three Months Ended March 31, 2026 [IFRS] (Summary)

May 12, 2026

Company name: Nissha Co., Ltd.

Stock exchange listing: Tokyo Stock Exchange

Code number: 7915

URL: <https://www.nissha.com/english>

Representative: Junya Suzuki, Chairman of the Board and Group CEO

Contact: Daisuke Inoue, Director of the Board, Senior Executive Vice President, CFO

Phone: +81-75-811-8111

Scheduled date of commencing dividend payments: –

Availability of supplementary briefing material on financial results: Available

Schedule of financial results briefing session: Scheduled (for institutional investors)

(Amounts of less than one million yen are rounded down)

1. Consolidated Financial Results for the Three Months Ended March 31, 2026 (January 1, 2026 to March 31, 2026)

(1) Consolidated Operating Results (cumulative)

(% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Total comprehensive income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Three months ended March 31, 2026	45,790	(3.5)	750	(47.6)	751	26.8	447	331.4	422	–	2,256	–
Three months ended March 31, 2025	47,442	1.5	1,432	13.8	592	(64.6)	103	(91.4)	12	(99.0)	(3,765)	–

	Basic earnings per share		Diluted earnings per share	
	Yen		Yen	
Three months ended March 31, 2026	8.92		–	
Three months ended March 31, 2025	0.26		–	

(Notes) 1. The Company finalized the provisional accounting treatment pertaining to business combination in the fiscal year ended December 31, 2025, and reflected the details of the finalization of the provisional accounting treatment on figures for the three months ended March 31, 2025.

2. The percentage change in profit attributable to owners of parent from the previous corresponding period is presented as "-" because it is 1,000% or more.

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
	Million yen	Million yen	Million yen	%
As of March 31, 2026	251,947	118,538	117,035	46.5
As of December 31, 2025	250,120	117,872	115,316	46.1

2. Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
Fiscal year ended December 31, 2025	Yen –	Yen 25.00	Yen –	Yen 25.00	Yen 50.00
Fiscal year ending December 31, 2026	–				
Fiscal year ending December 31, 2026 (Forecast)		25.00	–	25.00	50.00

(Note) Revision of cash dividend forecast most recently announced: No

3. Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2026 (January 1, 2026 to December 31, 2026)

(% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	94,000	(3.1)	1,800	(29.6)	1,300	18.9	300	–	6.33
Full year	198,000	1.6	7,000	73.3	5,700	60.5	3,200	219.4	67.49

(Note) 1. Revision of consolidated financial results forecast most recently announced: Yes

2. Changes from the previous corresponding period are calculated based on figures after retrospective adjustments, reflecting the finalization of the provisional accounting treatment for the business combination conducted in the fiscal year ended December 31, 2025.

3. The percentage change in profit attributable to owners of parent from the previous corresponding first half is presented as "-" because it is 1,000% or more.

Qualitative Information on Consolidated Financial Results for the Period under Review

During the fiscal year ended December 31, 2025, the provisional accounting treatment pertaining to Cathtek, LLC, which was acquired on October 1, 2024, as well as SHIGAKEN PHARM. IND. CO., LTD., which was acquired on January 8, 2025, was finalized. Accordingly, revised figures based on the finalization of the provisional accounting treatment have been used for the comparative analysis with figures for the three months ended March 31, 2025.

Effective from the first quarter ended March 31, 2026, the categories within our reportable segments were partially reclassified, and the financial results for the three months ended March 31, 2025 were compared and analyzed in accordance with the reclassified categories.

Explanation of operating results

The Group's Mission is to use the diverse capabilities of its people and core technologies as an engine for growth to create highly competitive, feature-rich products and services that realize customer value and contribute to better lives for all.

Guided by this Mission, as our Sustainability Vision (our long-term vision), we aim to create economic and social value by contributing to solving global social issues in the priority markets of Medical, Mobility, and Sustainable Materials, with the integration and orchestration of the diverse talents of our people and our technologies. Under the current 8th Medium-term Business Plan, we aim to achieve stable growth and capital efficiency improvement. Accordingly, we are working to improve and stabilize profitability through strengthening the business portfolio we have built up to date.

During the three months ended March 31, 2026, the global economy showed a gradual recovery, despite factors such as the turmoil in the Middle East situation and the rise in the resource prices weighing down on the economy. In the United States, consumer sentiment showed signs of weakening against the backdrop of a softening labor market, slowing the pace of economic expansion. In Europe, the economy was supported mainly by domestic demand and remained firm. In China, despite improvements in external demand, a prolonged stagnant real estate market and sluggish domestic demand led to continued weakness in the economy. Meanwhile, in Japan, the economy recovered modestly, supported by improvements in the employment and income environment as well as solid capital investment.

Under these conditions, during the three months ended March 31, 2026, product demand stayed solid in the Industrial Materials segment in the field of decorations and in the Medical segment. On the other hand, in the Devices segment, product demand for tablets declined significantly and both net sales and operating profit decreased, compared to the same period of the previous year.

As a result, regarding the financial results for the three months ended March 31, 2026, net sales were ¥45,790 million (a decrease of 3.5% as compared to the same period of the previous year), operating profit was ¥750 million (a decrease of 47.6% as compared to the same period of the previous year) and profit attributable to owners of parent was ¥422 million (an increase of 3,358.6% as compared to the same period of the previous year).

Following is an overview by business segment.

Industrial Materials

In the Industrial Materials segment, we mainly offer proprietary technologies that enable the creation of added value on the surfaces of various materials. IMD and IML, which facilitate simultaneous in-mold decoration, design and function adding of plastic products, are extensively used in mobility components and home appliances in global markets. Also, the metallized paper, which unites the properties of metallic luster and printing friendliness, has the largest market share in the industry as sustainable materials for beverages and foods on a global basis.

During the three months ended March 31, 2026, while demand showed signs of weakening in the field of sustainable materials, demand for exterior functional components for mobility in the field of decorations grew and net sales increased year on year. On the other hand, operating profit decreased year on year mainly due to costs associated with the production in the field of decorations and decrease in demand for sustainable materials.

As a result, segment sales for the three months ended March 31, 2026 were ¥19,529million (an increase of 4.0% as compared to the same period of the previous year). Segment profit (operating profit) was ¥708 million (a decrease of 30.1% as compared to the same period of the previous year).

Devices

In the Devices segment, we produce components and module products that pursue precision and functionality. Our main products, film-based touch sensors are adopted mainly in tablets and handheld terminals (logistics related) in global markets. During the three months ended March 31, 2026, primarily due to the decline in demand for tablets, net sales decreased year on year. Despite the positive effects of improved productivity on these demand trends, operating profit decreased year on year.

As a result, segment sales for the three months ended March 31, 2026, were ¥10,400 million (a decrease of 23.3% as compared to the same period of the previous year). Segment profit (operating profit) was ¥392 million (a decrease of 54.6% as compared to the same period of the previous year).

Medical

The Medical segment is a business segment that contributes to healthy and affluent life through the contract design/development and manufacturing organization (CDMO) services for medical devices and pharmaceuticals. For medical devices, we provide CDMO services for major medical device manufacturers, especially for those in North America and Europe, with products such as surgical instruments for minimal invasive medical treatments and medical wearable sensors used for a wide range of therapeutic areas. For pharmaceuticals, primarily in Japan, we develop our CDMO business for over-the-counter (OTC) drugs such as cold medicines and analgesic antipyretics, and also manufacture and market our own prescription pharmaceuticals and quasi-drugs.

During the three months ended March 31, 2026, both net sales and operating profit increased year on year, driven by steady demand for our CDMO services for medical devices and pharmaceuticals.

As a result, segment sales for the three months ended March 31, 2026, were ¥14,134 million (an increase of 3.7% as compared to the same period of the previous year). Segment profit (operating profit) was ¥841 million (an increase of 13.3% as compared to the same period of the previous year).